Neuroone Medical Technologies (NMTC) Common Equity (2010 - 2026)

Neuroone Medical Technologies' Common Equity history runs 17 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• Quarterly Common Equity rose 350.97% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 350.97% YoY) and the FY2025 annual result came in at $7.1 million, up 760.39% from the prior year.
• Common Equity was $5.1 million for Q1 2026 at Neuroone Medical Technologies, down from $6.4 million in the prior quarter.
• Across five years, Common Equity topped out at $13.1 million in Q1 2022 and bottomed at $822013.0 in Q3 2024.
• A 5-year average of $5.9 million and a median of $5.5 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 86.85% — and 2025, when it jumped 760.39%.
• Neuroone Medical Technologies' Common Equity stood at $8.2 million in 2022, then tumbled by 45.93% to $4.4 million in 2023, then slumped by 33.56% to $2.9 million in 2024, then jumped by 118.1% to $6.4 million in 2025, then slipped by 20.69% to $5.1 million in 2026.
• Business Quant data shows NMTC's Common Equity at $5.1 million in Q1 2026, $6.4 million in Q4 2025, and $7.1 million in Q3 2025.